Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minoru Takemoto

Showing results (91-100 of 144) with videos related to

Pageof 15
Sort By:
Geriatrics & Gerontology International|August 24, 2024
Recommendations for cancer screening and surveillance in patients with Werner syndromeKazuto Aono, Yoshiro Maezawa, Hisaya Kato, et al.
Journal of Diabetes Investigation|June 9, 2023
Weight loss improves inflammation by T helper 17 cells in an obese patient with psoriasis at high risk for cardiovascular eventsYoshiro Maezawa, Yusuke Endo, Satomi Kono, et al.
International Journal of Cardiology|December 4, 2014
Efficacy of HMG-CoA reductase inhibitors in the prevention of cerebrovascular attack in 1016 patients older than 75 years among 4014 type 2 diabetic individualsToshio Hayashi, Kiyoshi Kubota, Seinosuke Kawashima, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 9, 2010
CCN3 inhibits neointimal hyperplasia through modulation of smooth muscle cell growth and migrationTatsushi Shimoyama, Shûichi Hiraoka, Minoru Takemoto, et al.
Pharmacotherapy|September 29, 2023
Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reductionAyano Tsukagoshi-Yamaguchi, Masaya Koshizaka, Ryoichi Ishibashi, et al.
BMJ Open|May 12, 2017
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)Masaya Koshizaka, Ko Ishikawa, Takahiro Ishikawa, et al.
Scientific Reports|May 17, 2016
A novel podocyte gene, semaphorin 3G, protects glomerular podocyte from lipopolysaccharide-induced inflammationRyoichi Ishibashi, Minoru Takemoto, Yoshihiro Akimoto, et al.
Journal of Nephrology|December 23, 2016
Combination of cilostazol and probucol protected podocytes from lipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanismsPeng He, Harukiyo Kawamura, Minoru Takemoto, et al.
Journal of Diabetes Research|March 31, 2015
Pituitary adenylate cyclase-activating polypeptide protects glomerular podocytes from inflammatory injuriesKenichi Sakamoto, Kyoko Kuno, Minoru Takemoto, et al.
Endocrine Journal|January 19, 2010
Hypoglycemia due to ectopic secretion of insulin-like growth factor-I in a patient with an isolated sarcoidosis of the spleenYuiko Ogiwara, Seijiro Mori, Mizuki Iwama, et al.
Pageof 15

Showing results (91-100 of 144) with videos related to

Sort By:
Pageof 15
Geriatrics & Gerontology International|August 24, 2024
Recommendations for cancer screening and surveillance in patients with Werner syndromeKazuto Aono, Yoshiro Maezawa, Hisaya Kato, et al.
Journal of Diabetes Investigation|June 9, 2023
Weight loss improves inflammation by T helper 17 cells in an obese patient with psoriasis at high risk for cardiovascular eventsYoshiro Maezawa, Yusuke Endo, Satomi Kono, et al.
International Journal of Cardiology|December 4, 2014
Efficacy of HMG-CoA reductase inhibitors in the prevention of cerebrovascular attack in 1016 patients older than 75 years among 4014 type 2 diabetic individualsToshio Hayashi, Kiyoshi Kubota, Seinosuke Kawashima, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 9, 2010
CCN3 inhibits neointimal hyperplasia through modulation of smooth muscle cell growth and migrationTatsushi Shimoyama, Shûichi Hiraoka, Minoru Takemoto, et al.
Pharmacotherapy|September 29, 2023
Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reductionAyano Tsukagoshi-Yamaguchi, Masaya Koshizaka, Ryoichi Ishibashi, et al.
BMJ Open|May 12, 2017
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)Masaya Koshizaka, Ko Ishikawa, Takahiro Ishikawa, et al.
Scientific Reports|May 17, 2016
A novel podocyte gene, semaphorin 3G, protects glomerular podocyte from lipopolysaccharide-induced inflammationRyoichi Ishibashi, Minoru Takemoto, Yoshihiro Akimoto, et al.
Journal of Nephrology|December 23, 2016
Combination of cilostazol and probucol protected podocytes from lipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanismsPeng He, Harukiyo Kawamura, Minoru Takemoto, et al.
Journal of Diabetes Research|March 31, 2015
Pituitary adenylate cyclase-activating polypeptide protects glomerular podocytes from inflammatory injuriesKenichi Sakamoto, Kyoko Kuno, Minoru Takemoto, et al.
Endocrine Journal|January 19, 2010
Hypoglycemia due to ectopic secretion of insulin-like growth factor-I in a patient with an isolated sarcoidosis of the spleenYuiko Ogiwara, Seijiro Mori, Mizuki Iwama, et al.
Pageof 15